Nexalin Technology (NXL) Registration filing summary

Company overview and business model

• Designs and develops non-invasive neurostimulation devices for mental health conditions, focusing on anxiety, insomnia, depression, and other disorders.

• Devices use proprietary waveform technology, with Gen-2 and Gen-3 models targeting deeper brain stimulation at 15 milliamps.

• Revenue is currently derived from legacy device leases and consumables; new device sales in the U.S. are paused pending regulatory clearance.

• Pursuing a virtual clinic model for home-based treatment, integrating telehealth and physician oversight.

• Joint venture in China enables clinical development and commercialization of Gen-2 devices, with regulatory approvals for insomnia and depression.

Financial performance and metrics

• Reported comprehensive loss of $4.7 million for the year ended December 31, 2023, and $1.0 million for the quarter ended March 31, 2024.

• Accumulated deficit was $78.1 million as of March 31, 2024.

• Not currently cash flow positive; expects continued operating losses and increased expenses for R&D, regulatory, and commercialization activities.

Use of proceeds and capital allocation

• Net proceeds from the offering will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• Proceeds may also be allocated to strategic opportunities such as acquisitions, joint ventures, or licensing.